Please assess the completion status of the following clinical trial:

Trial Title: Follow-up Study of Autologous Adipose-derived Stem Cells (ANTG-ASC) for the Complex Fistula (ANTG-ASC-211)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* the patients who have participated in ANTG-ASC-210 clinical trial~* the patients with complete closure at week 8 after last injection in ANTG-ASC-210 trials~* the patients who submit written informed consents and is able to obey requirements of trials~Exclusion Criteria:~* a patient who has a history of variant Creutzfeldt Jacobs disease or related diseases~* a patient who is allergic to anesthetics, bovine derived proteins or a fibrin glue~* a patient who has an autoimmune disease~* a patient who has infectious diseases such as hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV)~* a patient who has a symptom of septicemia or active tuberculosis (contain tuberculosis of anus and rectum)~* a patient who is pregnant or breast feeding~* a patient who is not willing to use effective contraceptive methods during the study~* a patient who has inflammatory Bowel disease~* a patient who is sensitive to fibrin glue~* a patient who have a clinically relevant history of abuse of alcohol or drugs, habitual smoker (who smoked more than 20 cigarettes a day)~* a patient who is not able to understand the objective of this study or to comply with the study requirements~* a patient who is considered to have a significant disease which can impact the study by investigator~* a patient who is considered not suitable for the study by investigator~* a patient who had a history of surgery for malignant tumor within the last five years (except carcinoma in situ)~* a patient who has multisystemic wasting syndrome (such as tuberculosis, Diabetes, Thyroid disorders, tumor, etc.)~* a patient who has taken cytotoxic drugs (such as immunosuppressants, corticosteroid, cytotoxic chemotherapy, anticoagulants, etc.) during long-term

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low dose group (Type: None): Group1. Low dose group
- High dose group (Type: None): Group2. High dose group

Based on this trial design, predict the completion outcome and termination type (if applicable).